← Oncology Approval Tracker

FDA DECISION ·

Hyftor

sirolimus · Nobelpharma

FDA approvalNew formulationFacial angiofibroma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Topical sirolimus for tuberous-sclerosis-associated facial angiofibromas in adults and children age six or older.

LAMPGEN ANALYSIS

Why it matters

The gel provides a localized option for these benign facial tumors.

What research teams should watch

Confirm the tuberous sclerosis diagnosis and age and document the treated lesions and application instructions.

PRIMARY RECORDS

Sources